Trial Profile

Long-Term Follow-Up of AT-GTX-501 scAAV9 Gene Transfer in Subjects With CLN6 Batten Disease

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sesiclenegene cosaparvovec (Primary)
Indications Neuronal ceroid lipofuscinosis
Focus Adverse reactions
Sponsors Amicus Therapeutics

Most Recent Events

02 Feb 2023 Planned End Date changed from 1 Jan 2035 to 1 Oct 2024.
02 Feb 2023 Planned primary completion date changed from 1 Jan 2035 to 1 Oct 2024.
22 Dec 2021 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com